A retrospective single-center study to determine drug sustainability, efficacy, and safety of biologic therapies in elderly inflammatory bowel disease patients
Latest Information Update: 26 Jul 2022
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 26 Jul 2022 New trial record